

Guidelines for Poster Session

The followings are the guidelines to prepare your poster presentation.

1. Poster Session Location/Schedule

Poster Session	
Location	Lobby of Lotus Hall (3F), The Shilla Jeju Hotel, Jeju, Korea
Install	March 01 (Fri.) ~ 11:00
Dismantle	March 03 (Sun.) 10:00 ~
Poster Session - March 01 (Fri.)	
- Code	PP- # (Odd Number)
- Q&A Time	March 01 (Fri.) 13:00~14:00
Poster Session - March 02 (Sat.)	
- Code	PP- # (Even Number)
- Q&A Time	March 02 (Sat.) 14:00~14:30

* All poster presenters are encouraged to be at their poster panels for discussion with participants during the poster Q&A time.

2. Poster Size

- **Paper (Poster) size should be A0 118.9cm (Height) x 84cm (Width).**

3. Regulations

- Posters should be readable by viewers from one meter away. The poster title, author(s)'s name(s) and affiliation(s) should appear on the top. The message should be clear and understandable without oral explanation.
- Poster shows the main content or the main results of the paper.
- Only adhesive tape will be available to attach your poster to the panel. (The tapes will be provided at the desk in the poster session area.)
- All presenters should remove posters on the Dismantle time. If not, posters will be removed by staff members without notice and the organizing committee will not take responsibilities for any damages or losses of posters.
- The organizing committee does not provide presenters with any poster printing services. Please print your poster where you can print (ex: near your school or hospital).

TWC 2019 Poster Presentation

PP Code	PP Date	PP Time	Abstract Code	Presenter	Nation	Affiliation	Topic	Abstract Title
PP-001	Mar. 01 (Fri.)	13:00-14:00	AF0006	Ahmad Zaid Zaniat	Malaysia	Kuala Lumpur General Hospital	Clinical	MIBG Therapy for Relapsed Large Pheochromocytoma Post Debulking Surgery and Chemoembolization: A Case Report and Early Experience of Kuala Lumpur General Hospital
PP-002	Mar. 02 (Sat.)	14:00-14:30	AF0105	Aleksander .	Indonesia	Padjadjaran University / Hasan Sadikin General Hospital	Clinical	The New Experience of RSHS Using I-131 MIBG in Management of Late Stage of Neuroblastoma
PP-003	Mar. 01 (Fri.)	13:00-14:00	AF0098	Alvita Siswoyo	Indonesia	Indonesia Society of Nuclear Medicine	Clinical	Complete Response of Radioactive Iodine Therapy in an Unusual Case of Hyperfunctioning Metastatic Thyroid Cancer: A Case Report
PP-004	Mar. 02 (Sat.)	14:00-14:30	AF0113	Andreas Lim	Indonesia	Hasan Sadikin General Hospital Bandung / Universitas Padjadjaran Bandung	Clinical	Is Tc-99m ethambutol (EMB) scintigraphy able to identify unknown lesions of patients with suspected tuberculosis (TB)?
PP-005	Mar. 01 (Fri.)	13:00-14:00	AF0099	Ankit Watts	India	PGIMER, Chandigarh	Clinical	68 Ga Pentixafor PET/CT imaging targeting CXCR4 chemokine receptors: First Asian Experience in Lung Carcinoma
PP-006	Mar. 02 (Sat.)	14:00-14:30	AF0087	Ayu Dewi	Indonesia	Dharmais Cancer Hospital	Clinical	Iodine-refractory thyroid cancer: A review of 9 cases.
PP-007	Mar. 01 (Fri.)	13:00-14:00	AF0082	Bangbang Aryanto	Indonesia	Hasan Sadikin Hospital	Clinical	Prospective study of myelosuppression effect on palliative bone pain therapy with Samarium-153 EDTMP: a preliminary study
PP-008	Mar. 02 (Sat.)	14:00-14:30	AF0051	Benjapa Khiewwan	Thailand	The Faculty of Medicine Siriraj Hospital	Clinical	Ra-223 therapy for bony metastases in Castration-Resistant Prostate Cancer: First experience in Siriraj Hospital
PP-009	Mar. 01 (Fri.)	13:00-14:00	AF0064	Bolormaa Ganbaatar	Mongolia	FIRST STATE CENTRAL OF HOSPITAL	Clinical	Prediction of silent brain metastasis in patients with T1 and T2 lung adenocarcinoma on F-18 FDG PET/CT: Is there an additive role to guide further brain evaluation in patients with early T-stage on c
PP-010	Mar. 02 (Sat.)	14:00-14:30	AF0010	Bui Cong	Vietnam	Ha Noi Medical University	Clinical	STUDY ON THE RELATIONSHIP BETWEEN THE FDG-PET/CT MAXSUV OF PRIMARY TUMOR AND EGFR MUTATION STATUS IN LUNG ADENOCARCINOMA
PP-011	Mar. 01 (Fri.)	13:00-14:00	AK0081	Chae Moon Hong	Korea	School of Medicine, Kyungpook National University Kyungpook National University Hospital	Clinical	Prognostic implication of changes in dynamic risk stratification of 2015 ATA guidelines
PP-012	Mar. 02 (Sat.)	14:00-14:30	AF0071	Chaw Hsu Win	Myanmar	Myanmar Nuclear Medicine Society	Clinical	Role of PET/CT: Emerging theranostic approach in management of differentiated thyroid cancer in Myanmar
PP-013	Mar. 01 (Fri.)	13:00-14:00	AF0053	Danielle Meyrick	Australia	GenesisCare	Clinical	Treatment of Predominantly Lymph Node Metastatic Prostate Cancer with 177Lu-PSMA Radioligand Therapy
PP-014	Mar. 02 (Sat.)	14:00-14:30	AF0060	Fatima Begum	Bangladesh	National Institute of Nuclear Medicine & Allied Sciences, Bangladesh Atomic Energy	Clinical	Follow up of Refractory to Radioiodine Differentiated Thyroid Carcinoma Patients at Tertiary Institute

TWC 2019 Poster Presentation

PP Code	PP Date	PP Time	Abstract Code	Presenter	Nation	Affiliation	Topic	Abstract Title
PP-015	Mar. 01 (Fri.)	13:00-14:00	AF0036	Febby Hutomo	Indonesia	Indonesian Society of Nuclear Medicine	Clinical	Correlation between serum Tg-on and persistent disease in patients with well differentiated thyroid carcinoma.
PP-016	Mar. 02 (Sat.)	14:00-14:30	AK0143	Hongyoon Choi	Korea	Seoul National University Hospital	Clinical	Deep learning only by normal brain PET identify unheralded brain anomalies
PP-017	Mar. 01 (Fri.)	13:00-14:00	AF0023	Ivana Mulyanto	Indonesia	ISNM	Clinical	Low versus high dose radioiodine remnant ablation for intermediate risk differentiated thyroid carcinoma: A meta-analysis
PP-018	Mar. 02 (Sat.)	14:00-14:30	AF0059	Ivana Mulyanto	Indonesia	ISNM	Clinical	Lung Metastases when Left Untreated May Lead to Hyperthyroidism: A Case Report
PP-019	Mar. 01 (Fri.)	13:00-14:00	AF0132	Jamilla Cecilia Gomez	Philippines	National Kidney and Transplant Institute	Clinical	18F-FDG PET/CT of Neurolymphomatosis with a background of Ovarian Carcinoma
PP-020	Mar. 02 (Sat.)	14:00-14:30	AF0031	Jasmin Ferdous	Bangladesh	Bangladesh Atomic Energy Commission	Clinical	Radioiodine treated Differentiated Thyroid Cancer patients with lung metastases: Follow up analysis for more than 10 yrs
PP-021	Mar. 01 (Fri.)	13:00-14:00	AF0043	Jingjing Zhang	Germany	Zentralklinik Bad Berka	Clinical	First-in-human study of a novel somatostatin receptor antagonist 68Ga-NODAGA-LM3 for molecular imaging of paraganglioma patients
PP-022	Mar. 02 (Sat.)	14:00-14:30	AF0044	Jingjing Zhang	Germany	Zentralklinik Bad Berka	Clinical	Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Grade 3 Neuroendocrine Neoplasms (NEN)
PP-023	Mar. 01 (Fri.)	13:00-14:00	AF0040	Jingjing Zhang	Germany	Zentralklinik Bad Berka	Clinical	¹⁷⁷ Lu-PSMA-617 radioligand therapy in mCRPC patients with a single functioning kidney
PP-024	Mar. 02 (Sat.)	14:00-14:30	AF0041	Jingjing Zhang	Germany	Zentralklinik Bad Berka	Clinical	Prognostic value of 18F-FDG PET/CT in a large cohort of 495 patients with advanced neuroendocrine neoplasms (NEN) treated with peptide receptor radionuclide therapy (PRRT)
PP-025	Mar. 01 (Fri.)	13:00-14:00	AF0042	Jingjing Zhang	Germany	Zentralklinik Bad Berka	Clinical	Long-term Nephrotoxicity After PRRT: Myth or Reality?
PP-026	Mar. 02 (Sat.)	14:00-14:30	AF0039	Jingjing Zhang	Germany	Zentralklinik Bad Berka	Clinical	Pregnancy and delivery after PRRT without sequelae
PP-027	Mar. 01 (Fri.)	13:00-14:00	AK0080	Jinyeong Choi	Korea	Department of Transdisciplinary Studies, Seoul National University	Clinical	The relationship and prognosis value of metabolic and genomic heterogeneity based on integrative analysis of FDG PET and genomic data in head and neck squamous cell carcinoma
PP-028	Mar. 02 (Sat.)	14:00-14:30	AF0013	K.m. Ng	Hong Kong	HKU	Clinical	Xi-chromosome Reactivation as a Therapeutic approach for X-linked cardiomyopathies.

TWC 2019 Poster Presentation

PP Code	PP Date	PP Time	Abstract Code	Presenter	Nation	Affiliation	Topic	Abstract Title
PP-029	Mar. 01 (Fri.)	13:00-14:00	AF0123	Ko-Han Lin	Taiwan	Taipei Veterans General Hospital	Clinical	Theranostic approach using FBPA-PET in boron neutron capture therapy
PP-030	Mar. 02 (Sat.)	14:00-14:30	AF0071	Kyin Myint	Myanmar	Myanmar Nuclear Medicine Society	Clinical	Role of PET/CT: Emerging theranostic approach in management of differentiated thyroid cancer in Myanmar
PP-031	Mar. 01 (Fri.)	13:00-14:00	AF0102	Madhav Yadav	India	ALL INDIA INSTITUTE OF MEDICAL SCIENCES	Clinical	¹⁷⁷ Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy and quality of life assessment
PP-032	Mar. 02 (Sat.)	14:00-14:30	AF0072	Mairah Razi	Pakistan	Shaukat Khanum Memorial Cancer Hospital and Research Centre	Clinical	Impact of I-131 SPECT/CT on American Thyroid Association (ATA) risk stratification in differentiated thyroid cancer
PP-033	Mar. 01 (Fri.)	13:00-14:00	AF0007	Manoj Gupta	India	Rajiv Gandhi Cancer Institute and Research Centre	Clinical	Safety profile and therapeutic efficacy of one cycle of [¹⁷⁷ Lu] PSMA in end stage metastatic castration resistant prostate cancer patients with low performance status
PP-034	Mar. 02 (Sat.)	14:00-14:30	AF0038	Md. Sayedur Miah	Bangladesh	BANGLADESH ATOMIC ENERGY COMMISSION	Clinical	Effects of Thyroxine Withdrawal in Patients with Differentiated Thyroid Cancer
PP-035	Mar. 01 (Fri.)	13:00-14:00	AF0124	Megawatti Setiabudi	Indonesia	RSUP Dokter Hasan Sadikin	Clinical	Assessment of Bone Metastases in Patients with Prostate Cancer ? A Comparison between ^{99m} Tc-MDP Bone Scintigraphy and ¹⁷⁷ Lu-CC 34 PSMA Preliminary Study
PP-036	Mar. 02 (Sat.)	14:00-14:30	AK0111	Minseok Suh	Korea	Seoul National University Hospital	Clinical	¹⁸ F-FDG PET parameters reflecting microsatellite instability status and immune microenvironment in stage II and III proximal colon cancer
PP-037	Mar. 01 (Fri.)	13:00-14:00	AF0083	Muhammad Fahmi	Indonesia	Hasan Sadikin Hospital	Clinical	The Incidence of Repeated Therapy in Hyperthyroid Patients That Received Initial NaI-131 Empirically at Department of Nuclear Medicine and Molecular Imaging Dr. Hasan Sadikin General Hospital Bandung
PP-038	Mar. 02 (Sat.)	14:00-14:30	AF0035	Muhammad Numair Younis	Pakistan	INMOL Cancer Hospital	Clinical	¹⁷⁷ Lu-PRRT IN PATIENTS OF NEUROENDOCRINE TUMORS AT INMOL; 10 MONTHS' EXPERIENCE AT FIRST THERANOSTICS CENTER OF PAKISTAN
PP-039	Mar. 01 (Fri.)	13:00-14:00	AF0110	Norazlina Mat Nawi	Malaysia	Hospital Universiti Sains Malaysia	Clinical	EFFICACY OF RECOMBINANT HUMAN THYROID STIMULATING HORMONE (rhTSH) ON WHOLE BODY IODINE CLEARANCE IN DIFFERENTIATED THYROID CANCER
PP-040	Mar. 02 (Sat.)	14:00-14:30	AF0090	Nyamgerel Batdelger	Mongolia	State first central hospital of Mongolia	Clinical	ULTRASOUNDS OF FETAL UROGENITAL CONGENITAL ABNORMALITIES
PP-041	Mar. 01 (Fri.)	13:00-14:00	AF0014	Omar Alonso	Uruguay	Uruguayan Center of Molecular Imaging (CUDIM)	Clinical	Is [¹⁸ F]-AIF-PSMA-HBED-CC and ¹⁷⁷ Lu-PSMA-617 a potential theragnostic tandem for prostate cancer?
PP-042	Mar. 02 (Sat.)	14:00-14:30	IF0069	Patricia Bautista	Philippines	St. Luke's Medical Center	Clinical	The Establishment of Gallium-68 and Lutetium-177 Theranostics in the Philippines

TWC 2019 Poster Presentation

PP Code	PP Date	PP Time	Abstract Code	Presenter	Nation	Affiliation	Topic	Abstract Title
PP-043	Mar. 01 (Fri.)	13:00-14:00	IF0057	Pham Phuong	Vietnam	Bach Mai Hospital	Clinical	ENDEAVORS TO IMPLEMENT THERANOSTICS IN VIETNAM
PP-044	Mar. 02 (Sat.)	14:00-14:30	AF0112	Pupree Mutsuddy	Bangladesh	Seoul National University Hospital	Clinical	Prognostic Value of Tumor Necrosis at FDG PET in Non-Small Cell Lung Cancer Patients
PP-045	Mar. 01 (Fri.)	13:00-14:00	AF0115	Puspa Handayani	Indonesia	Hasan Sadikin General Hospital Bandung / Universitas Padjadjaran Bandung	Clinical	METASTASIS PATTERN IN PROSTATE CANCER BASED ON BONE SCINTIGRAPHY EXAMINATION
PP-046	Mar. 02 (Sat.)	14:00-14:30	AF0142	Qaid Shagera	Korea	Seoul National University Hospital	Clinical	An additive prognostic value of metabolic tumor volume on baseline F-18 FDG-PET/CT to NCCN-IPI in patients with diffuse large B-cell lymphoma: Further stratification of the high-risk group in NCCN-IPI
PP-047	Mar. 01 (Fri.)	13:00-14:00	AF0030	Rahima Perveen	Bangladesh	Bangladesh Atomic Energy Commission	Clinical	Thyroid Function Evaluation in Newborn of Mothers with Differentiated Thyroid Carcinoma after Radioiodine Treatment at Tertiary Hospital
PP-048	Mar. 02 (Sat.)	14:00-14:30	AF0093	Horacio Amaral	Chile	PositronMed	Clinical	PRRT as part of a treatment plan in gastroenteropancreatic-NET in Chile: results of our local experience.
PP-049	Mar. 01 (Fri.)	13:00-14:00	AF0020	Riccardo Laudicella	Italy	University Hospital G.Martino, Messina	Clinical	PRRT Retreatments: Renal Function Evaluation
PP-050	Mar. 02 (Sat.)	14:00-14:30	AF0021	Riccardo Laudicella	Italy	University Hospital G.Martino, Messina	Clinical	Complete response in a pancreatic NEN with liver metastasis after PRRT in association with Lanreotide autogel/depot: design of the Prelude study
PP-051	Mar. 01 (Fri.)	13:00-14:00	AF0033	Salvatore Pignata	Italy	University of Messina	Clinical	Prognostic validity of dual tracer PET/CT in the PRRT enrollment of GEP-NET Patients
PP-052	Mar. 02 (Sat.)	14:00-14:30	AF0034	Salvatore Pignata	Italy	University of Messina	Clinical	Peptide Receptor Radionuclide Therapy and Somatostatin 'Cold' Analogues therapy in the treatment of GEP-NET Patients: our center' experience.
PP-053	Mar. 01 (Fri.)	13:00-14:00	AF0048	Sean Yan	Singapore	Singapore General Hospital	Clinical	Ga-68 DOTATATE PET/CT evaluation for PRRT in Adult Neuroblastoma
PP-054	Mar. 02 (Sat.)	14:00-14:30	AF0019	Son Mai	Vietnam	Tran Hung Dao Hospital	Clinical	The Quantitative Analysis of Post- Selective Internal Radiation Therapy (SIRT) 90Y Microspheres PET/CT in Hepatocellular Carcinoma in Comparison With 99mTc-Labelled Macroaggregated Albumin (MAA)
PP-055	Mar. 01 (Fri.)	13:00-14:00	AF0015	Su Oo	Myanmar	MINISTRY OF HEALTH AND SPORTS	Clinical	Accuracy of CKD- EPI Equation in Correlation with 99mTc DTPA Renogram to Estimate GFR of Chronic Kidney Disease at North Okkalapa General Hospital, Myanmar
PP-056	Mar. 02 (Sat.)	14:00-14:30	AF0116	Tangming Peng	China	university of macau	Clinical	Is single low-profile visualized intraluminal support (LVIS) assisted coiling of wide-necked ruptured multiple intracranial aneurysms in one-stage feasible?

TWC 2019 Poster Presentation

PP Code	PP Date	PP Time	Abstract Code	Presenter	Nation	Affiliation	Topic	Abstract Title
PP-057	Mar. 01 (Fri.)	13:00-14:00	AF0108	Tin Maung Thein	Myanmar	Perfect Myanmar Molecular Imaging and Therapy Center	Clinical	Incidental finding in bone scan
PP-058	Mar. 02 (Sat.)	14:00-14:30	AF0114	Tri Suciarti	Indonesia	Hasan Sadikin General Hospital Bandung / Universitas Padjadjaran Bandung	Clinical	Analysis Uptake 177 LU-CC 34 PSMA in salivary glands of prostate cancer patients
PP-059	Mar. 01 (Fri.)	13:00-14:00	AF0140	Wulan Apriliani	Indonesia	Padjadjaran University	Clinical	Xerostomia Assessment with Xerostomia Questionnaire in Patients with Prostate Cancer Underwent Diagnostic Procedures Using Lu177-CC34
PP-060	Mar. 02 (Sat.)	14:00-14:30	AF0029	Yan Ho Hui	Hong Kong	Queen Elizabeth Hospital	Clinical	Initial experience on the clinical safety and treatment efficacy of peptide receptor radionuclide therapy (PRRT): local experience in a single center
PP-061	Mar. 01 (Fri.)	13:00-14:00	AF0058	Yaping Luo	China	Peking Union Medical College Hospital	Clinical	Chemokine receptor CXCR4-targeted PET/CT with 68Ga-pentixafor shows superiority to 18F-FDG in evaluation of multiple myeloma
PP-062	Mar. 02 (Sat.)	14:00-14:30	AF0089	Yulia Kurniawati	Indonesia	Indonesia society of nuclear medicine	Clinical	Therapeutical Response Evaluation on Hyperthyroidism Using I-131 Fixed Dose
PP-063	Mar. 01 (Fri.)	13:00-14:00	AF0085	Zulhendri Syauki	Indonesia	Universitas Padjadjaran	Clinical	Discrepancy Between Exercise ECG (Treadmill) with Myocardial Perfusion Imaging in Patient with Suspect CAD
PP-064	Mar. 02 (Sat.)	14:00-14:30	AF0107	Aisyah Elliyanti	Indonesia	Faculty of Medicine Universitas Andalas	Chemistry and Pharmacy	Characterization Uptake and Cytotoxic of Radioiodine in MCF-7 and SKBR-3 Breast Cancer Cell Lines
PP-065	Mar. 01 (Fri.)	13:00-14:00	AF0144	Ali Azhdarinia	USA	The University of Texas Health Science Center at Houston	Chemistry and Pharmacy	Targeting of somatostatin receptor subtype-2 for fluorescence-guided surgery
PP-066	Mar. 02 (Sat.)	14:00-14:30	AK0078	Ayoung Pyo	Korea	Chonnam National University Hwasun Hospital	Chemistry and Pharmacy	Comparison of [18F]DMFB and [18F]DMPY2 as PET imaging agents for malignant melanoma
PP-067	Mar. 01 (Fri.)	13:00-14:00	AF0056	Frank Roesch	Germany	Johannes Gutenberg-University Mainz	Chemistry and Pharmacy	Radiolabeling of a TA-MUC1 specific monoclonal antibody and its corresponding single chain fragment with 89Zr, 44Sc and 177Lu for breast cancer theranostics
PP-068	Mar. 02 (Sat.)	14:00-14:30	AF0068	Colin Biggin	Australia	Clarity Pharmaceuticals	Chemistry and Pharmacy	Establishing centralised manufacture of next generation theranostics (Cu-64/Cu-67).
PP-069	Mar. 01 (Fri.)	13:00-14:00	AF0091	Dirk Mueller	Germany	Zentralklinik Bad Berka GmbH	Chemistry and Pharmacy	Cyclotron produced Ga-68 and their post-processing using solid targets - initial results.
PP-070	Mar. 02 (Sat.)	14:00-14:30	AF0088	Dirk Mueller	Germany	Zentralklinik Bad Berka GmbH	Chemistry and Pharmacy	Targeted Alpha-Particle Therapeutics ? Adaptation of Clinical Routinely produced Ac-225-labeled Radiopharmaceuticals

TWC 2019 Poster Presentation

PP Code	PP Date	PP Time	Abstract Code	Presenter	Nation	Affiliation	Topic	Abstract Title
PP-071	Mar. 01 (Fri.)	13:00-14:00	AF0062	Dongyoul Lee	USA	University of Iowa	Chemistry and Pharmacy	Enhancing SSTR2-targeted alpha-particle therapy for neuroendocrine tumors with everolimus and histone deacetylase inhibitors
PP-072	Mar. 02 (Sat.)	14:00-14:30	AF0101	Elisabeth Eppard	Chile	PositronPharma	Chemistry and Pharmacy	Synthesis and preliminary evaluation of a novel FAP-inhibitor containing squaric acid coupled DOTA
PP-073	Mar. 01 (Fri.)	13:00-14:00	AF0070	Michelle Parker	Australia	Clarity Pharmaceuticals	Chemistry and Pharmacy	Development of a new bifunctional PSMA ligand as a theranostic for prostate cancer
PP-074	Mar. 02 (Sat.)	14:00-14:30	AF0055	Euy Sung Moon	Germany	Johannes Gutenberg University Mainz	Chemistry and Pharmacy	AAZTA.Squaric acid as a promising conjugate for radiolabelling monoclonal antibodies with lutetium-177 under mild conditions
PP-075	Mar. 01 (Fri.)	13:00-14:00	AF0137	Hai-Hao Han	China	East China University of Science and Technology	Chemistry and Pharmacy	Sensitive Fluorescence Detection of Peroxynitrite Enabled by a Nanohybrid in the Process of Inflammation
PP-076	Mar. 02 (Sat.)	14:00-14:30	AF0097	Hanane Lahnif	Germany	Johannes Gutenberg - University Mainz	Chemistry and Pharmacy	In vitro evaluation of novel squaric acid coupled AAZTA5 and DATA conjugated KuE targeting vectors
PP-077	Mar. 01 (Fri.)	13:00-14:00	AK0074	Ho Young Kim	Korea	Seoul National University	Chemistry and Pharmacy	In the assessment of biodistribution and metabolism for α -methylation on 18F-labeled tryptophan derivative.
PP-078	Mar. 02 (Sat.)	14:00-14:30	AF0076	Irfan Ullah Khan	Pakistan	INMOL Cancer Hospital, New Campus Road, Lahore-54600	Chemistry and Pharmacy	Capacity Building in Theranostics: Initial Experience at INMOL-Lahore, being First Theranostics Center in Pakistan
PP-079	Mar. 01 (Fri.)	13:00-14:00	AK0125	Ji Yong Park	Korea	Seoul National University	Chemistry and Pharmacy	Anti-tumor effect of CD206+ TAM-specific depletion with finely tuned clickable liposomes-encapsulated clodronate.
PP-080	Mar. 02 (Sat.)	14:00-14:30	AK0126	Ji Yong Park	Korea	Seoul National University	Chemistry and Pharmacy	Early detection of metastasis using a clickable albumin nano-platform by Targeting CD206+ Tumor-Associated Macrophages
PP-081	Mar. 01 (Fri.)	13:00-14:00	AK0022	Ji Youn Lee	Korea	Seoul National University	Chemistry and Pharmacy	The Development of Evans Blue and Mannosylated Human Serum Albumin (MSA) Conjugate For Sentinel Lymph Node Mapping
PP-082	Mar. 02 (Sat.)	14:00-14:30	AF0018	Karen Ho	Australia	Royal Adelaide Hospital	Chemistry and Pharmacy	Synthesis of 68Ga-human serum albumin nanocolloid: A potential lymphoscintigraphy imaging agent
PP-083	Mar. 01 (Fri.)	13:00-14:00	AF0050	Lukas Greifenstein	Germany	Johannes Gutenberg-University Mainz	Chemistry and Pharmacy	Simple functionalization of chelators with square acid using the example of TRAM.PSMA
PP-084	Mar. 02 (Sat.)	14:00-14:30	AF0092	Mike Sathekge	South Africa	University of Pretoria	Chemistry and Pharmacy	Preparing optimal human doses of 68Ga-DOTA-tate using a kit radiolabeling solution supporting personalized radioendotherapy

TWC 2019 Poster Presentation

PP Code	PP Date	PP Time	Abstract Code	Presenter	Nation	Affiliation	Topic	Abstract Title
PP-085	Mar. 01 (Fri.)	13:00-14:00	AF0046	Mohd Farhan	Macau	University of Macau	Chemistry and Pharmacy	IGF-1 induced migration and invasion of Uveal melanoma cells is mediated by FoxO3a transcription factor
PP-086	Mar. 02 (Sat.)	14:00-14:30	AK0047	Nadeem Ahmed Lodhi	Korea	Seoul National University Hospital	Chemistry and Pharmacy	Development of ^{99m} Tc-Labeled Human Serum Albumin with Prolonged Circulation by Chelate-then Click Approach: A Potential Blood Pool Imaging Agent
PP-087	Mar. 01 (Fri.)	13:00-14:00	AF0119	Neneng Rosilawati	Indonesia	world Council on Isotopes	Chemistry and Pharmacy	EFFECT OF DIFFERENT HEATING DURATION ON ⁶⁸ GA-PSMA-HBED-CC RADIOLABELLING EFFICIENCY FOR PROSTATE CANCER IMAGING
PP-088	Mar. 02 (Sat.)	14:00-14:30	IK0086	Pyeong Seok Choi	Korea	Korea Atomic Energy Research Institute	Chemistry and Pharmacy	Effectively Zr-89 Incorporated on the Inside of Iron Oxide Nanoparticles without Chelators and Its In-vivo Behavior in the Tumor Xenograft Mouse Model
PP-089	Mar. 01 (Fri.)	13:00-14:00	AK0103	Sang Bong Lee	Korea	Daegu-Gyeongbuk Medical Innovation Foundation	Chemistry and Pharmacy	PEGylated crushed gold shell-radiolabeled core nanoballs for in vivo bio imaging application with dual positron emission tomography and cerenkov luminescent imaging
PP-090	Mar. 02 (Sat.)	14:00-14:30	IK0073	Sanghee Lee	Korea	Graduate School of Convergence Science and Technology, Seoul National University, Seoul,	Chemistry and Pharmacy	TSPO targeted theranostics for bladder cancer imaging and photodynamic therapy
PP-091	Mar. 01 (Fri.)	13:00-14:00	AF0032	Shuai Li	China	University of Macau	Chemistry and Pharmacy	Berberine protected RPE cells from H ₂ O ₂ induced oxidative stress via the activation of the AMPK pathway
PP-092	Mar. 02 (Sat.)	14:00-14:30	AF0084	Sven Stadlbauer	Germany	German Cancer Research Center	Chemistry and Pharmacy	Imaging of PD-L1 for immunotherapy monitoring
PP-093	Mar. 01 (Fri.)	13:00-14:00	AF0052	Frank Roesch	Germany	Johannes Gutenberg-University Mainz	Chemistry and Pharmacy	Synthesis and radiolabeling of a novel squaric acid coupled AAZTA5-KuE for theranostics of prostate cancer
PP-094	Mar. 02 (Sat.)	14:00-14:30	AF0117	Vikas Kumar	India	SAM HIGGINBOTTOM UNIVERSITY OF AGRICULTURE, TECHNOLOGY & SCIENCES	Chemistry and Pharmacy	Solid Lipid Nanoparticles of Umbelliferone and Its Anticancer Molecular Mechanisms: Computational Approaches vs In vivo study
PP-095	Mar. 01 (Fri.)	13:00-14:00	AK0079	Wooseung Lee	Korea	Seoul National University	Chemistry and Pharmacy	Development of Radiolabeled Europium embedded Nanoparticle for in vivo Imaging and gamma ray induced Photodynamic Therapy
PP-096	Mar. 02 (Sat.)	14:00-14:30	AF0045	Xia Zhao	Macau	university of Macau	Chemistry and Pharmacy	Activation of AMPK pathway is involved in the protection of Metformin on PC12 cells and hippocampal neurons against H ₂ O ₂ -induced oxidative damage
PP-097	Mar. 01 (Fri.)	13:00-14:00	AF0004	Xue Xue	China	Nanjing First Hospital, Nanjing Medical University	Chemistry and Pharmacy	Aquaporin-4 deficiency reduces TGF- β 1 in mouse midbrains and exacerbates pathology in experimental Parkinson's disease
PP-098	Mar. 02 (Sat.)	14:00-14:30	AF0096	Jingjing Zhang	Germany	Zentralklinik Bad Berka	Physics and Dosimetry	Serial Lu-177 PSMA radioligand therapy: Variation in the absorbed radiation dose and PSA response

TWC 2019 Poster Presentation

PP Code	PP Date	PP Time	Abstract Code	Presenter	Nation	Affiliation	Topic	Abstract Title
PP-099	Mar. 01 (Fri.)	13:00-14:00	AF0065	Michelle Parker	Australia	Clarity Pharmaceuticals	Physics and Dosimetry	Experimental work up and validation of ⁶⁷ Cu quantitative SPECT
PP-100	Mar. 02 (Sat.)	14:00-14:30	AK0017	Donghwi Hwang	Korea	Seoul National University	Physics and Dosimetry	Attenuation map generation in whole-body PET/MRI based on a deep neural network applied to simultaneously reconstructed activity and attenuation and Dixon MRI
PP-101	Mar. 01 (Fri.)	13:00-14:00	AK0012	Haewook Park	Korea	Seoul National University	Physics and Dosimetry	A hand-held ultra-low dose intraoperative x-ray imager: Large-animal imaging study using agar-based lung nodule model
PP-102	Mar. 02 (Sat.)	14:00-14:30	AK0066	Jun Yeon Won	Korea	Seoul National University Hospital	Physics and Dosimetry	Highly Integrated FPGA-only Data Acquisition System Using Single-ended Memory Interface Input Receivers for Time-of-Flight PET Scanners
PP-103	Mar. 01 (Fri.)	13:00-14:00	AF0139	Lutfun Nisa	Bangladesh	Society of Nuclear Medicine Bangladesh	Physics and Dosimetry	Radio-Iodine Treatment of Hyperthyroidism in Bangladesh: Patient Specific Dosimetry Planning
PP-104	Mar. 02 (Sat.)	14:00-14:30	AF0100	Mahmood Nazari	Germany	Hybrid2020	Physics and Dosimetry	Fully automated, robust and fast organ segmentation for voxel-based dose planning
PP-105	Mar. 01 (Fri.)	13:00-14:00	AF0104	Saleh Salehi Zahabi	Iran	Kermanshah university of medical science	Physics and Dosimetry	¹⁷⁷ Lu-SPION-Chitosan: New Theranostic and Dual-modality Imaging Probes in Nuclear Medicine
PP-106	Mar. 02 (Sat.)	14:00-14:30	IK0026	Seung Kwan Kang	Korea	Seoul National University	Physics and Dosimetry	SPECT angular sampling and scan time reduction using deep neural networks
PP-107	Mar. 01 (Fri.)	13:00-14:00	AK0011	Seungeun Lee	Korea	Seoul National University	Physics and Dosimetry	Effect of inter-detector scatter recovery on performance of a brain-dedicated PET system
PP-108	Mar. 02 (Sat.)	14:00-14:30	IF0061	Zeenat Jabin	Bangladesh	Bangladesh Atomic Energy Commission	Physics and Dosimetry	Validation of radioiodine scan based dosimetry protocol in differentiated thyroid cancer patients
PP-109	Mar. 01 (Fri.)	13:00-14:00	AF0063	Abdelmjid Aiboud	Morocco	National Energy Center of Nuclear Science and Technology of Morocco	Others	Development of a new method for the microbiological analysis of Iodine 131
PP-110	Mar. 02 (Sat.)	14:00-14:30	AF0109	Aisyah Elliyanti	Indonesia	Faculty of Medicine Universitas Andalas	Others	Analysis Natrium Iodide Symporter Expression of Thyroid Tumor Patients in Padang City
PP-111	Mar. 01 (Fri.)	13:00-14:00	AF0037	Azmal Sarker	Bangladesh	Institute of Nuclear Medicine and Allied Sciences, Mitford, Dhaka	Others	Theranostic paradox: A report of two cases
PP-112	Mar. 02 (Sat.)	14:00-14:30	AF0016	Bernard Ponsard	Belgium	Belgian NuclearResearch Centre (SCK.CEN)	Others	Production of Sn-117m in the BR2 High-Flux Reactor

TWC 2019 Poster Presentation

PP Code	PP Date	PP Time	Abstract Code	Presenter	Nation	Affiliation	Topic	Abstract Title
PP-113	Mar. 01 (Fri.)	13:00-14:00	AF0024	Chirag Vyas	Korea	Korea Atomic Energy Research Institute	Others	Overview of Radionuclide Production Program with RFT-30 Cyclotron
PP-114	Mar. 02 (Sat.)	14:00-14:30	AK0106	Chiwoo Oh	Korea	Seoul National University	Others	Impact of Cold Exposure in Brown Adipose Tissue Imaging using TSPO PET Tracer
PP-115	Mar. 01 (Fri.)	13:00-14:00	AK0120	Do Won Hwang	Korea	Seoul National University, College of Medicine	Others	Graphene oxide-quenching-based fluorescence in situ hybridization (G-FISH) to detect RNA in tissue: simple and fast tissue RNA diagnostics
PP-116	Mar. 02 (Sat.)	14:00-14:30	AF0067	Michelle Parker	Australia	Clarity Pharmaceuticals	Others	Comparability of ⁶⁷ Cu-SARTATE and ¹⁷⁷ Lu-DOTA-octreotate efficacy in a preclinical model of neuroendocrine tumours
PP-117	Mar. 01 (Fri.)	13:00-14:00	AK0118	Eunji Lee	Korea	Seoul National University Hospital	Others	PROTECTIVE EFFECT OF EXTRACELLULAR VESICLES RELEASED FROM THE NEURAL STEM CELLS ON 6-HYDROXYDOPAMINE INDUCED PATHOLOGICAL CONDITION OF PARKINSON'S DISEASE
PP-118	Mar. 02 (Sat.)	14:00-14:30	AF0009	Fan Qiu	China	Nanjing First Hospital Affiliated to Nanjing Medical University	Others	¹⁷⁷ Lu-DOTA-TOC Inhibits Cell Proliferation by Inducing Autophagy and G2/M Cell Arrest in Neuroendocrine Prostate Cancer Cell
PP-119	Mar. 01 (Fri.)	13:00-14:00	AK0133	Geonnyeong Jang	Korea	Seoul National University Hospital	Others	Observation of RNA Modification as a New Theranostics Target in Neuroinflammation
PP-120	Mar. 02 (Sat.)	14:00-14:30	AK0130	Ho Rim Oh	Korea	Seoul National University	Others	In vivo PET imaging of brown adipose tissue using translocator protein 18 kDa (TSPO)-targeting PET: a comparative study with F-18 FDG
PP-121	Mar. 01 (Fri.)	13:00-14:00	AK0136	Hoon Young Suh	Korea	Seoul National University Hospital	Others	Study of Diagnostic and Therapeutic Targets via Neuroinflammation and Blood-Brain Barrier Disruption in Early Animal Model of Alzheimer's Disease
PP-122	Mar. 02 (Sat.)	14:00-14:30	AK0129	Jin Hye Oh	Korea	Seoul National University	Others	Enhanced breast cancer proliferation by cancer exosome-stimulated glial cells and the potential of cancer-derived exosome as a therapeutic target
PP-123	Mar. 01 (Fri.)	13:00-14:00	AF0095	Joana Marie Almazan	Philippines	St. Luke's Medical Center	Others	Technical Experiences On Theranostics In The Philippines: Radiolabeling, Quality Control And Patient Administration Setup
PP-124	Mar. 02 (Sat.)	14:00-14:30	AK0077	Jun Young Lee	Korea	Korea Atomic Energy Research Institute	Others	Biomimetic design for avoiding immune barriers of macrophage with RBC membrane cloaked ⁸⁹ Zr labeled nanoparticles
PP-125	Mar. 01 (Fri.)	13:00-14:00	IK0127	Kyungmin Kim	Korea	Seoul National University Hospital	Others	Comparative analysis of TSPO-targeting PET/MR and recruitment of peripheral immune cells using bioluminescence imaging in neuro-inflammatory mouse model
PP-126	Mar. 02 (Sat.)	14:00-14:30	AF0095	Melvin Estonactoc	Philippines	ST. LUKE'S MEDICAL CENTER	Others	Technical Experiences on Theranostics in the Philippines: Radiolabeling, Quality Control and Patient Administration Setup

TWC 2019 Poster Presentation

PP Code	PP Date	PP Time	Abstract Code	Presenter	Nation	Affiliation	Topic	Abstract Title
PP-127	Mar. 01 (Fri.)	13:00-14:00	AF0121	Michael Torres	Philippines	St. Luke's Medical Center	Others	Technical Experiences on Theranostics in the Philippines: Radiolabeling, Quality Control and Patient Administration Setup
PP-128	Mar. 02 (Sat.)	14:00-14:30	IF0138	Rini Shintawati	Indonesia	Hasan Sadikin Hospital	Others	BIODISTRIBUTION OF ¹⁷⁷ LUTETIUM-(R)-NODAGA-PSMA IN MALE WISTAR STRAIN RATS
PP-129	Mar. 01 (Fri.)	13:00-14:00	AK0128	Seo Young Kang	Korea	Seoul National University Hospital	Others	Modulation of Glucose Metabolism by Cancer-derived Extracellular Vesicle in Tumor
PP-130	Mar. 02 (Sat.)	14:00-14:30	AK0122	Seok-Yong Lee	Korea	Seoul National University Hospital	Others	Role of TSPO ligand-receptor binding on TSPO-VDAC interaction
PP-131	Mar. 01 (Fri.)	13:00-14:00	AK0145	Seunggyun Ha	Korea	Seoul National University	Others	Developmental changes of brain metabolic network in ADHD rats
PP-132	Mar. 02 (Sat.)	14:00-14:30	AK0134	Tae-Young Ha	Korea	Ajou medical university	Others	Caveolin-1 increases cell to cell transmission in parkinson's disease.
PP-133	Mar. 01 (Fri.)	13:00-14:00	AF0005	Tetsuya Sakashita	Japan	National Institutes for Quantum and Radiological Science and Technology	Others	RNA-seq reveals tumor radiation response and novel molecular targets on α -emitting meta-[At-211]-astato-benzylguanidine therapy for malignant pheochromocytoma
PP-134	Mar. 02 (Sat.)	14:00-14:30	IF0054	Frank Roesch	Germany	Johannes Gutenberg-University Mainz	Others	[²²⁵ Ac]Ac-DOTAZOL for α -therapy of bone metastases: Synthesis and in vivo evaluation
PP-135	Mar. 01 (Fri.)	13:00-14:00	AK0135	Yoori Choi	Korea	Seoul National University Hospital	Others	Diagnosis of Alzheimer's disease through functional brain connectivity represented by structural changes of brain cells
PP-136	Mar. 02 (Sat.)	14:00-14:30	AK0131	Youngsun Lee	Korea	Seoul National University	Others	The alteration of expression of long noncoding RNA associated with miRNA101-a in Alzheimer's disease model